In the treatment of HCC with MV vaccine strain MV-Edm improved by adopting CD8+NKG2D+ cells, MV-Edm-infected HCC can enhance the anti-tumor activity of CD8+NKG2D+ cells, which provide a novel and clinically relevant strategy for HCC treatment [13]. Here, CD8A is linked to neoplasm.